Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus chemotherapy for relapsed or refractory pediatric and young adult ALL/LL
NL-OMON46576Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Complete response rate. Started Oct 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NL-OMON46576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46576.